Shots:
- Telix has entered into a strategic agreement to lead a merger with ITM Isotope Technologies Munich, with Telix shareholders expected to own ~76.3% & ITM shareholders ~23.7% of Telix shares upon completion
- As per the deal, Telix will acquire 100% of ITM for $1.65B upfront, comprising $1.25B in the form of 105.8M Telix shares, $302M in assumed net debt, & $96M in management equity rollover & transaction expenses
- Telix may pay up to $700M in additional contingent consideration, incl. ~$250M tied to FDA approvals of ITM-11 across three NET indications & ~$450M based on FY’30 global sales exceeding $150M, payable in cash or shares at Telix’s election
Ref: Telix | Image: Telix & ITM | Press Release
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
